Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Bladder Cancer

Free Subscription 18.02.2019 1 Acta Pharmacol Sin 1 Am J Pathol 1 Ann Surg Oncol 3 Arch Esp Urol 1 BJU Int 1 BMC Cancer 1 Br J Cancer 1 Can Urol Assoc J 1 Cancer Lett 1 Cancer Sci 1 Clin Immunol 2 Curr Opin Urol 1 Curr Treat Options Oncol 1 Eur J Nutr 1 Eur Urol 2 Int J Biol Sci 1 Int J Mol Sci 1 J Cell Biochem 1 J Obstet Gynaecol Res 1 J Ovarian Res 9 J Urol 1 Medicine (Baltimore) 1 Nat Commun 1 Nat Rev Urol 3 Nihon Hinyokika Gakkai Zasshi 1 Physiol Rep 1 Prog Urol 1 Sci Rep 1 Support Care Cancer 1 Transl Res 2 Urol Oncol 1 Urologiia 1 World J Surg Oncol

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Acta Pharmacol Sin

1. CAO YP, Sun JY, Li MQ, Dong Y, et al
   Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells.
   Acta Pharmacol Sin. 2019 Feb 14. pii: 10.1038/s41401-018-0205.
   PubMed     Text format     Abstract available
   
   

   
   Am J Pathol

2. WITZKE KE, Grosserueschkamp F, Jutte H, Horn M, et al
   Integrated Fourier Transform Infrared Imaging and Proteomics for Identification of a Candidate Histochemical Biomarker in Bladder Cancer.
   Am J Pathol. 2019 Feb 9. pii: S0002-9440(18)30739.
   PubMed     Text format     Abstract available
   
   

   
   Ann Surg Oncol

3. CLEMENTS MB, Krupski TL, Culp SH
   Robotic-Assisted Surgery for Upper Tract Urothelial Carcinoma: A Comparative Survival Analysis.
   Ann Surg Oncol. 2018;25:2550-2562.
   PubMed     Text format     Abstract available
   
   

   
   Arch Esp Urol

4. ELIZALDE BENITO FX, Ucar Terren A, Monzon Alebesque F, Urra Palos M, et al
   Bladder cancer with Indian ink.
   Arch Esp Urol. 2019;72:89-90.
   PubMed     Text format     Abstract available
   
   
5. GOMEZ RIVAS J, Eguibar Gonzalez A, Tortolero Blanco L, Aguilera Bazan A, et al
   [Usefulness of photodynamic diagnosis in high-grade Bladder Cancer and subsequent BCG failure. Bibliographic review.]
   Arch Esp Urol. 2019;72:2-8.
   PubMed     Text format     Abstract available
   
   
6. PABO-CARRASCO S, Vallejo-Benitez A, Carmona-Pinelo E, Umbria-Jimenez S, et al
   [Nested variant Transitional Cell Carcinoma. Report of two cases and bibliographic review.]
   Arch Esp Urol. 2018;71:794-799.
   PubMed     Text format     Abstract available
   
   

   
   BJU Int

7. HUGAR LA, Lopa SH, Yabes JG, Yu JA, et al
   Palliative Care Use Among Patients with Bladder Cancer.
   BJU Int. 2019 Feb 13. doi: 10.1111/bju.14708.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

8. GOULET CR, Champagne A, Bernard G, Vandal D, et al
   Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling.
   BMC Cancer. 2019;19:137.
   PubMed     Text format     Abstract available
   
   

   
   Br J Cancer

9. DUFOUR F, Silina L, Neyret-Kahn H, Moreno-Vega A, et al
   TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer.
   Br J Cancer. 2019 Feb 15. pii: 10.1038/s41416-019-0397.
   PubMed     Text format     Abstract available
   
   

   
   Can Urol Assoc J

10. KULKARNI GS, Black PC, Sridhar SS, Kapoor A, et al
    Canadian Urological Association guideline: Muscle-invasive bladder cancer.
    Can Urol Assoc J. 2019 Jan 31. pii: cuaj.5902. doi: 10.5489/cuaj.5902.
    PubMed     Text format    
    
    

    
    Cancer Lett

11. XIE R, Chen X, Chen Z, Huang M, et al
    Polypyrimidine tract binding protein 1 promotes lymphatic metastasis and proliferation of bladder cancer via alternative splicing of MEIS2 and PKM.
    Cancer Lett. 2019 Feb 8. pii: S0304-3835(19)30071.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Sci

12. WANG B, Pan W, Yang M, Yang W, et al
    Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
    Cancer Sci. 2019;110:489-498.
    PubMed     Text format     Abstract available
    
    

    
    Clin Immunol

13. LIU K, Sun E, Lei M, Li L, et al
    BCG-induced formation of neutrophil extracellular traps play an important role in bladder cancer treatment.
    Clin Immunol. 2019 Feb 13. pii: S1521-6616(18)30633.
    PubMed     Text format     Abstract available
    
    

    
    Curr Opin Urol

14. MUKHERJEE N, Wheeler KM, Svatek RS
    Bacillus Calmette-Guerin treatment of bladder cancer: a systematic review and commentary on recent publications.
    Curr Opin Urol. 2019 Feb 11. doi: 10.1097/MOU.0000000000000595.
    PubMed     Text format     Abstract available
    
    
15. NASER-TAVAKOLIAN A, Ghodoussipour S, Djaladat H
    Upper urinary tract recurrence following bladder cancer therapy: a review of surveillance and management.
    Curr Opin Urol. 2019 Feb 11. doi: 10.1097/MOU.0000000000000598.
    PubMed     Text format     Abstract available
    
    

    
    Curr Treat Options Oncol

16. EINSTEIN DJ, Sonpavde G
    Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
    Curr Treat Options Oncol. 2019;20:12.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Nutr

17. WITLOX WJA, van Osch FHM, Brinkman M, Jochems S, et al
    An inverse association between the Mediterranean diet and bladder cancer risk: a pooled analysis of 13 cohort studies.
    Eur J Nutr. 2019 Feb 8. pii: 10.1007/s00394-019-01907.
    PubMed     Text format     Abstract available
    
    

    
    Eur Urol

18. GOLDSTEIN MR, Mascitelli L
    Re: John L. Gore, Jonathan L. Wright. Can We Prevent Bladder Cancer Recurrences? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.008.
    Eur Urol. 2019 Feb 11. pii: S0302-2838(19)30093.
    PubMed     Text format    
    
    

    
    Int J Biol Sci

19. SU Y, Yang W, Jiang N, Shi J, et al
    Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin resistance.
    Int J Biol Sci. 2019;15:441-452.
    PubMed     Text format     Abstract available
    
    
20. DENG Y, Bi R, Guo H, Yang J, et al
    Andrographolide Enhances TRAIL-Induced Apoptosis via p53-Mediated Death Receptors Up-Regulation and Suppression of the NF-small ka, CyrillicB Pathway in Bladder Cancer Cells.
    Int J Biol Sci. 2019;15:688-700.
    PubMed     Text format     Abstract available
    
    

    
    Int J Mol Sci

21. OEYEN E, Hoekx L, De Wachter S, Baldewijns M, et al
    Bladder Cancer Diagnosis and Follow-Up: The Current Status and Possible Role of Extracellular Vesicles.
    Int J Mol Sci. 2019;20.
    PubMed     Text format     Abstract available
    
    

    
    J Cell Biochem

22. MAJ M, Kokocha A, Bajek A, Drewa T, et al
    The effects of adipose-derived stem cells on CD133-expressing bladder cancer cells.
    J Cell Biochem. 2019 Feb 11. doi: 10.1002/jcb.28436.
    PubMed     Text format     Abstract available
    
    

    
    J Obstet Gynaecol Res

23. KONDO E, Maki S, Nii M, Yoshida K, et al
    Long-term survival of a patient with malignant transformation of extragonadal endometriosis treated solely with chemotherapy: A case report.
    J Obstet Gynaecol Res. 2018;44:2186-2189.
    PubMed     Text format     Abstract available
    
    

    
    J Ovarian Res

24. LEE YL, Lai CR, Yen MS
    Recurrent ovarian mixed germ cell tumor with unusual malignant transformation: a case report.
    J Ovarian Res. 2019;12:2.
    PubMed     Text format     Abstract available
    
    

    
    J Urol

25. CHANG SS
    Re: Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/01.JU.0000554055.35801.
    PubMed     Text format    
    
    
26. CHANG SS
    Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: .
    J Urol. 2019;201:442.
    PubMed     Text format    
    
    
27. CHANG SS
    Re: Human Epidermal Growth Factor Receptor 2 Expression is More Important than bacillus Calmette Guerin Treatment in Predicting the Outcome of T1G3 Bladder Cancer.
    J Urol. 2019;201:441-442.
    PubMed     Text format    
    
    
28. CHANG SS
    Re: Assessing Cancer Progression and Stable Disease after Neoadjuvant Chemotherapy for Organ-Confined Muscle-Invasive Bladder Cancer.
    J Urol. 2019;201:441.
    PubMed     Text format    
    
    
29. GRIEBLING TL
    Re: Impact of Psychiatric Illness on Decreased Survival in Elderly Patients with Bladder Cancer in the United States.
    J Urol. 2019 Feb 7. doi: 10.1097/JU.0000000000000162.
    PubMed     Text format    
    
    
30. CHANG SS
    Re: National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/01.JU.0000554054.35801.
    PubMed     Text format    
    
    
31. CHANG SS
    Re: Predicting Local Failure after Radical Cystectomy in Patients with Bladder Cancer: .
    J Urol. 2019 Feb 8. doi: 10.1097/JU.0000000000000166.
    PubMed     Text format    
    
    
32. GRIEBLING TL
    Re: The Challenges of Bacillus of Calmette-Guerin (BCG) Therapy for High Risk Non Muscle Invasive Bladder Cancer Treatment in Older Patients.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553995.59343.
    PubMed     Text format    
    
    
33. GRIEBLING TL
    Re: Comparing Survival Outcomes and Costs Associated with Radical Cystectomy and Trimodal Therapy for Older Adults with Muscle-Invasive Bladder Cancer.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553996.66966.
    PubMed     Text format    
    
    

    
    Medicine (Baltimore)

34. LIN T, Jin H, Gong L, Yu R, et al
    Surveillance of non-muscle invasive bladder cancer using fluorescence in situ hybridization: Protocol for a systematic review and meta-analysis.
    Medicine (Baltimore). 2019;98:e14573.
    PubMed     Text format     Abstract available
    
    

    
    Nat Commun

35. WU S, Ou T, Xing N, Lu J, et al
    Whole-genome sequencing identifies ADGRG6 enhancer mutations and FRS2 duplications as angiogenesis-related drivers in bladder cancer.
    Nat Commun. 2019;10:720.
    PubMed     Text format     Abstract available
    
    

    
    Nat Rev Urol

36. STONE L
    Treatment timing well tolerated in bladder cancer.
    Nat Rev Urol. 2019 Feb 11. pii: 10.1038/s41585-019-0162.
    PubMed     Text format    
    
    

    
    Nihon Hinyokika Gakkai Zasshi

37. ITO A, Takata R, Matsuo T, Kimura T, et al
    [COMPLETE RESECTION OF URACHAL CARCINOMA WITH SIGMOID COLON INVASION AFTER FOLFOX CHEMOTHERAPY: A CASE REPORT].
    Nihon Hinyokika Gakkai Zasshi. 2018;109:35-39.
    PubMed     Text format     Abstract available
    
    
38. MITA K, Kobatake K, Ohara S, Kato M, et al
    [LAPAROSCOPIC RADICAL CYSTECTOMY AT HIROSHIMA CITY ASA HOSPITAL].
    Nihon Hinyokika Gakkai Zasshi. 2018;109:1-6.
    PubMed     Text format     Abstract available
    
    
39. OZAWA M, Suenaga S, Ishii T, Suzuki H, et al
    [PRIMARY MALIGNANT LYMPHOMA OF THE BLADDER DIAGNOSED BY TRANSURETHRAL BLADDER TUMOR RESECTION: A CASE REPORT].
    Nihon Hinyokika Gakkai Zasshi. 2018;109:45-49.
    PubMed     Text format     Abstract available
    
    

    
    Physiol Rep

40. KISPERT S, Marentette J, McHowat J
    Cigarette smoking promotes bladder cancer via increased platelet-activating factor.
    Physiol Rep. 2019;7:e13981.
    PubMed     Text format     Abstract available
    
    

    
    Prog Urol

41. MARTIN T, Mantey K, Boissier R, Albert P, et al
    [The REVELA13 observatory to study new cases of bladder tumor among women living in Bouches-du-Rhone county].
    Prog Urol. 2018;28:935-941.
    PubMed     Text format     Abstract available
    
    

    
    Sci Rep

42. SIDDIQUI MR, Railkar R, Sanford T, Crooks DR, et al
    Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT).
    Sci Rep. 2019;9:2084.
    PubMed     Text format     Abstract available
    
    

    
    Support Care Cancer

43. CHUNG J, Kulkarni GS, Morash R, Matthew A, et al
    Assessment of quality of life, information, and supportive care needs in patients with muscle and non-muscle invasive bladder cancer across the illness trajectory.
    Support Care Cancer. 2019 Feb 14. pii: 10.1007/s00520-019-4649.
    PubMed     Text format     Abstract available
    
    

    
    Transl Res

44. MONTALBO R, Lozano JJ, Izquierdo L, Ingelmo-Torres M, et al
    Ability of a urine gene expression classifier to reduce the number of follow-up cystoscopies in bladder cancer patients.
    Transl Res. 2019 Feb 7. pii: S1931-5244(19)30025.
    PubMed     Text format     Abstract available
    
    

    
    Urol Oncol

45. KRAJEWSKI W, Zdrojowy R, Kolodziej A
    Purified protein derivative skin test-One swallow does not make a summer: Re: Purified protein derivative skin test reactions are associated with clinical outcomes of patients with nonmuscle invasive bladder cancer treated with induction Bacillus Calm
    Urol Oncol. 2019 Feb 5. pii: S1078-1439(19)30025.
    PubMed     Text format    
    
    
46. IMAI Y, Noda S, Matsuyama C, Shimizu A, et al
    Sex steroid hormone receptors in bladder cancer: Usefulness in differential diagnosis and implications in histogenesis of bladder cancer.
    Urol Oncol. 2019 Feb 6. pii: S1078-1439(19)30024.
    PubMed     Text format     Abstract available
    
    

    
    Urologiia

47. KOSOVA IV, Loran OB, Sinyakova LA, Gundorova LV, et al
    [A prognostic value of level of antiviral antibodies in the development of recurrence of bladder cancer].
    Urologiia. 2018;:86-94.
    PubMed     Text format     Abstract available
    
    

    
    World J Surg Oncol

48. DENG S, He SY, Zhao P, Zhang P, et al
    The role of oncostatin M receptor gene polymorphisms in bladder cancer.
    World J Surg Oncol. 2019;17:30.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: